Related Experiment Video
Updated: Jun 25, 2025
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Osimertinib Resistance via Histologic Transformation From Non-small Cell Lung Carcinoma to Carcinosarcoma
Paul Stegelmeier1, James A Dawson1, McKenzie Wallace2
1Department of Pathology and Anatomical Sciences, A.T. Still University Kirksville College of Osteopathic Medicine, Kirksville, USA.
Abstract:
Resistance to tyrosine kinase inhibitors (TKIs) in non-small cell lung carcinoma (NSCLC) remains a significant clinical challenge. Osimertinib, a third-generation TKI, has demonstrated efficacy in overcoming resistance, but novel resistance mechanisms continue to emerge. This case report presents a unique instance of histologic transformation from NSCLC to carcinosarcoma, representing a previously unreported manifestation of osimertinib resistance. We describe the clinical course of a 63-year-old female with epidermal growth factor receptor (EGFR)-mutant NSCLC who initially responded to osimertinib but eventually developed carcinosarcoma. The transformation was associated with additional EGFR mutations and alterations in RB and TP53. Despite aggressive treatment, the patient's condition deteriorated, emphasizing the limited therapeutic options for carcinosarcoma. This case underscores the need for further research to elucidate the molecular mechanisms behind histologic transformation and explore novel therapeutic strategies to address osimertinib resistance in NSCLC. Understanding and addressing these mechanisms are crucial for improving outcomes in patients facing this challenging form of resistance.
Insights
A rare case of non-small cell lung cancer (NSCLC) transformed into carcinosarcoma during osimertinib treatment highlights a new resistance mechanism. This histologic transformation presents significant challenges and necessitates further research into novel therapeutic strategies for advanced lung cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Non-small cell lung cancer (NSCLC) treatment often involves tyrosine kinase inhibitors (TKIs).
- Osimertinib, a third-generation TKI, is effective against EGFR-mutant NSCLC but acquired resistance remains a challenge.
- Emerging resistance mechanisms require continuous investigation to improve patient outcomes.
Observation:
- A 63-year-old female with EGFR-mutant NSCLC developed carcinosarcoma, a rare histologic transformation, during osimertinib therapy.
- This transformation was linked to secondary EGFR mutations and alterations in RB and TP53 tumor suppressor genes.
- The patient's condition progressed despite aggressive treatment for carcinosarcoma.
Findings:
- Histologic transformation to carcinosarcoma is a novel mechanism of osimertinib resistance in NSCLC.
- The transformation involved complex genetic alterations including additional EGFR mutations and TP53/RB pathway dysregulation.
- Carcinosarcoma exhibits limited therapeutic options and poor prognosis in this context.
Implications:
- This case highlights the need to identify and understand rare resistance mechanisms in NSCLC.
- Further research is crucial to elucidate the molecular drivers of histologic transformation.
- Developing novel therapeutic strategies targeting carcinosarcoma and overcoming TKI resistance is essential for improving NSCLC patient survival.
